Summit Therapeutics (SMMT) is drawing fresh attention as investors focus on ivonescimab, its bispecific antibody candidate for non-small cell lung cancer and colorectal cancer, and what this could mean for the stock.

At a recent share price of US$16.62, Summit Therapeutics has seen its 1 month share price return fall 24.73%, even though its 3 month share price return is up 3.29% and the 3 year total shareholder return is roughly 9x. This signals long term momentum despite recent pressure.

If you are looking beyond a single biotech story, this is a good moment to see what else is moving in healthcare related AI by checking out 34 healthcare AI stocks

With the stock down 35.7% over the past year and trading at a steep discount to analyst targets and some intrinsic value models, investors may ask whether Summit Therapeutics is undervalued or if the market is already pricing in its future growth prospects.

Most Popular Narrative: 43% Undervalued

The most followed narrative pegs Summit Therapeutics' fair value at $29.18, well above the recent $16.62 share price. It ties that gap directly to ambitious assumptions about ivonescimab's future earnings power.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to see what has to happen for that valuation to make sense? The narrative leans heavily on rapid revenue build, improving margins and a premium future earnings multiple. Curious how those moving parts fit together, and how much optimism is baked into each step?

Result: Fair Value of $29.18 (UNDERVALUED)

However, that upside story depends on successful ivonescimab approvals and trial outcomes, while heavy R&D spending and ongoing losses could pressure cash and future funding needs.

Another Angle On Valuation

The SWS DCF model paints a very different picture, with a fair value estimate of $92.82 per share versus the recent $16.62 price, implying a very large gap and an 82.1% discount. If that gap reflects aggressive long term forecasts, how comfortable are you with those inputs?

Next Steps

Reading mixed signals on Summit Therapeutics and its outlook? Take a closer look at the underlying data and sentiment, then decide how convincing the risk reward trade off really is with 2 key rewards and 3 important warning signs

Looking For More Investment Ideas?

If Summit Therapeutics is on your radar, do not stop there. Broaden your watchlist with other ideas that match your goals and comfort with risk.

• Target resilient cash generators with strong downside protection by scanning companies in the 67 resilient stocks with low risk scores.
• Spot potential mispricings by reviewing companies currently flagged as 49 high quality undervalued stocks.
• Hunt for future standouts before the crowd by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.